Multidrug resistance in acute myeloid leukemia: Potential new therapeutics

Journal of Nuclear Medicine

Volumn 49, Issue 9, 2008, Pages 1405-1407

  Weisburg, Jeffrey H ^a  

^a YESHIVA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CD15 ANTIGEN; DNA; GEMTUZUMAB OZOGAMICIN; GLYCOPROTEIN P; IMMUNOTOXIN; INTERLEUKIN 2; MICROSOMAL AMINOPEPTIDASE; MONOCLONAL ANTIBODY; MULTIDRUG RESISTANCE PROTEIN 1; PSC 883; QUININE; RADIOISOTOPE; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ALPHA RADIATION; AMINO ACID SEQUENCE; BETA RADIATION; CANCER CELL CULTURE; CANCER SURVIVAL; CANCER THERAPY; CYTOTOXICITY; GENE; HUMAN; IMMUNOTHERAPY; MEMBRANE POTENTIAL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; HUMANS; LEUKEMIA, MYELOID, ACUTE;

EID: 51349109215     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.050153     Document Type: Short Survey

References (28)

1. Chang G. Multidrug resistance ABC transporters. FEBS Lett. 2003;555:102-105.
2. Croop JM, Guild B, Gros P, Houseman DE. Genetics of multidrug resistance: relationship of a coned gene to the complete multidrug resistant phenotype. Cancer Res. 1987;47:5982-5988.
3. Hamada H, Tsuruo T. Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988;48:4926-4932.
4. Wadkins RM, Roepe PD. Biophysical aspects of P-glycoprotein-mediated multidrug resistance. Int Rev Cytol. 1997;171:121-165.
5. Weisburg JH, Curcio M, Caron PC, et al. The multidrug resistant phenotype confers immunological resistance. J Exp Med. 1996;183:2699-2704.
6. Weisburg JH, Roepe PD, Dzekunov S, Scheinberg DA. Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated cells. J Biol Chem. 1999;274:10877-10888.
7. Hirose M, Hosoi E, Hamano S, Jalili A. Multidrug resistance in hematological malignancy. J Med Invest. 2003;50:126-135.
8. McGrath MS, Rosenblum MG, Philips MR, Scheinberg DA. Immunotoxin resistance in multidrug resistant cells. Cancer Res. 2003;63:72-79.
9. Drach J, Gsur A, Hamilton G, et al. Involvement of P-glycoprotein in the transmembrane transport of IL-2, IL-4 and interferon-γ in normal human T lymphocytes. Blood. 1996;88:1747-1754.
10. Naito K, Takeshita A, Shigeno K, et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab, zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia. 2000;14:1436-1443.
11. LinenbergerML,HongT, FlowersD, et al.Multidrug-resistance phenotype and clinical response to gemtuzumab ozogamicin. Blood. 2001;98:988-994.
12. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254.
13. 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences. J Nucl Med. 2008;49:1546-1554.
14. Cassileth PA, Harrington DP, Appelbaum FR, et al. Chemotherapy compared with autologous or allogenic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649-1656.
15. Legrand O, Simonin G, Perrot J-Y, et al. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood. 1998;91:4480-4488.
16. Goldenberg DM. Target therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693-713.
17. Burke JM, Jurcic JG. Radioimmunotherapy of leukemia. Adv Pharmacol. 2004;51:185-208.
18. Todd WM. Acute myeloid leukemia and related conditions. Hematol Oncol Clin North Am. 2002;16:301-319.
19. Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood. 1983;62:124-132.
20. Griffin JD, Linch D, Sabbath K, et al. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res. 1984;8:521-534.
21. Mattes MJ. Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer. 2002;94(4 suppl):1215-1223.
22. Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control. 2002;9:106-113.
23. 111In-labeled antibodies to HER-2. Mol Cancer Ther. 2005;4:927-937.
24. Buchegger F, Perillo-Adamer F, Dupertuis YM, Delaloye AB. Auger radiation target into DNA: a therapy perspective. Eur J Nucl Med Mol Imaging. 2006;33:1352-1363.
25. van der Holt B, Lowenberg B, Burnett AK, et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR status at diagnosis. Blood. 2005;106:2646-2654.
26. Solary E, Drenou B, Campos L, et al. Quinine as amultidrug resistance inhibitor: a phase 3multicentric randomized study in adult de novo acutemyelogenous leukemia. Blood. 2003;102:1202-1210.
27. Tanimoto M, Scheinberg DA, Cordon-Cardo C, et al. Restricted expression of an early myeloid and monocytic cell surface. Leukemia. 1989;3:339-348.
28. 225Ac-HuM195, in nonhuman primates. J Nucl Med. 2004;45:129-137.